KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Other Non-Current Assets (2017 - 2025)

Moderna (MRNA) has disclosed Other Non-Current Assets for 8 consecutive years, with $594.0 million as the latest value for Q4 2024.

  • On a quarterly basis, Other Non-Current Assets fell 22.45% to $594.0 million in Q4 2024 year-over-year; TTM through Dec 2024 was $594.0 million, a 22.45% decrease, with the full-year FY2024 number at $594.0 million, down 22.45% from a year prior.
  • Other Non-Current Assets was $594.0 million for Q4 2024 at Moderna, down from $766.0 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $988.0 million in Q4 2022 to a low of $2.0 million in Q4 2020.
  • A 5-year average of $177.7 million and a median of $11.5 million in 2020 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: tumbled 81.82% in 2020, then soared 2805.88% in 2022.
  • Moderna's Other Non-Current Assets stood at $2.0 million in 2020, then skyrocketed by 1600.0% to $34.0 million in 2021, then skyrocketed by 2805.88% to $988.0 million in 2022, then dropped by 22.47% to $766.0 million in 2023, then decreased by 22.45% to $594.0 million in 2024.
  • Per Business Quant, the three most recent readings for MRNA's Other Non-Current Assets are $594.0 million (Q4 2024), $766.0 million (Q4 2023), and $988.0 million (Q4 2022).